Cyclosporine (Huons)(Cyclosporine (Huons)) - 药物靶点：CaN_在研适应症：干眼症_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Ciclosporin (Huons)、Clacier

+ [2]

靶点

CaN

作用机制

CaN抑制剂(钙神经素抑制剂)

治疗领域

眼部疾病

在研适应症

干眼症

非在研适应症-

原研机构

Huons Co., Ltd.

在研机构

Huons Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

韩国 (2018-11-26),

干眼症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C62H111N11O12

InChIKeyPMATZTZNYRCHOR-CGLBZJNRSA-N

CAS号59865-13-3

关联

15

项与 Cyclosporine (Huons) 相关的临床试验

CTRI/2023/03/050453

/ Not yet recruiting临床3期IIT

A prospective randomised study comparing the efficacy and safety of oral cyclosporine versus oral steroids in the management of refractory cases of oral lichen planus

开始日期2023-03-16

申办/合作机构-

NCT05057468

/ Unknown status临床3期IIT

Cyclosporine as a Second-line Treatment of Primary Autoimmune Hemolytic Anemia

the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous case reports and retrospective data. This study compares cyclosporin versus rituximab in steroid-refractory anemia.

开始日期2021-10-20

申办/合作机构

Assiut University

NCT04412785

/ Completed临床1期IIT

Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19

Phase 1 safety study to determine the tolerability, clinical effects, and changes in laboratory parameters of short course oral or IV cyclosporine (CSA) administration in patients with COVID-19 disease requiring oxygen supplementation but not requiring ventilator support.

开始日期2020-06-30

申办/合作机构

University of Pennsylvania

100 项与 Cyclosporine (Huons) 相关的临床结果

登录后查看更多信息

100 项与 Cyclosporine (Huons) 相关的转化医学

登录后查看更多信息

100 项与 Cyclosporine (Huons) 相关的专利（医药）

登录后查看更多信息

310

项与 Cyclosporine (Huons) 相关的文献（医药）

2025-02-01·Food Chemistry

Taste characterization and molecular docking study of novel umami flavor peptides in Yanjin black bone Chicken meat

Article

作者: Zhao, Ping ; Yang, Chaohui ; Ge, Changrong ; Ge, Xuehai ; Xiao, Zhichao ; Liang, Shuangmin

Five polypeptides with a potential umami taste were isolated and purified from Yanjin black bone chicken. However, the flavor characteristics and umami mechanism have not been clarified. The umami properties of these five peptides were investigated in this work using a range of analytical techniques, computer simulation, and sensory evaluation. HE-10 and TP-7 exhibited the strongest umami flavors. Furthermore, dose-response experiments showed that the umami peptides enhanced umami by generating peptide mineral chelates. Environmental scanning electron microscopy (ESEM) microstructural analyses supported this finding. The molecular docking results indicated that the five polypeptides bind to four critical amino acid residues, namely Glu217, Glu148, Asp216, and His145, of the T1R1/T1R3 receptor. The binding occurred through van der Waals, electrostatic interactions, hydrogen bonding, and hydrophobic interactions. The main surface forces implicated include aromatic interactions, hydrogen bonding, hydrophilicity, and solvent accessibility.

2024-11-18·British Journal of Dermatology

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK–Irish A-STAR register

Article

作者: Warren, Richard B ; Baden, Manisha ; Darné, Sharmela ; Cork, Michael J ; Popli, Urvi ; Warren, Richard B ; Brown, Victoria ; Ferguson, Leila ; Alexander, Helen ; Irvine, Alan D ; Ingram, John R ; Prieto-Merino, David ; Brown, Sara ; Wernham, Aaron ; Newell, Louise ; Johnston, Graham A ; Flohr, Carsten ; Hearn, Ross ; Wan, Mandy ; Patel, Prakash ; Burton, Tim ; Coker, Bola ; Ladoyanni, Effi ; Thompson, Ben ; Man, Irene ; Fadhil, May ; Wainman, Hannah ; Lambert, Alice ; Malek, Rayka ; Leitch, Claire ; Beattie, Paula ; Gribaleva, Elizaveta ; Ardern-Jones, Michael R ; Woolf, Richard ; Wahie, Shyamal ; Lunt, Mark ; Reynolds, Nick ; Sergeant, Ann ; Fahy, Caoimhe ; Yiu, Zenas Z N ; Cameron, Shona ; Llewellyn, Joanne ; Topliffe, Joanne ; Ogg, Graham ; Layton, Alison

AbstractBackgroundThe main conventional systemic treatments for atopic dermatitis (AD) are methotrexate (MTX) and ciclosporin (CyA). Dupilumab was the first novel systemic agent to enter routine clinical practice. There are no head-to-head randomized controlled trials or real-world studies comparing these agents directly. Network meta-analyses provide indirect comparative efficacy and safety data and have shown strong evidence for dupilumab and CyA.ObjectivesTo compare the real-world clinical effectiveness and safety of CyA, dupilumab and MTX in AD.MethodsWe compared the effectiveness and safety of these systemic agents in a prospective observational cohort study of adult and paediatric patients recruited into the UK–Irish Atopic eczema Systemic TherApy Register (A-STAR). Treatment effectiveness measures included Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM), Peak Pruritus Numerical Rating Scale (PP-NRS), Dermatology Life Quality Index (DLQI) and children’s DLQI (cDLQI). The minimum duration of treatment was 28 days and follow-up was 12 months. Adjusted Cox-regression analysis was used to compare the hazard ratios of achieving EASI-50, EASI-75 and EASI-90 over time, and linear mixed-effects models were used to estimate changes in efficacy scores. Treatment safety was assessed by examining adverse events (AEs) at follow-up visits.ResultsWe included 488 patients (311 adults and 177 children/adolescents) on dupilumab (n = 282), MTX (n = 149) or CyA (n = 57). CyA and MTX were primarily used as the first-line treatment, while dupilumab was mainly a second-line systemic treatment as per UK National Institute of Clinical and Care Excellence (NICE) recommendations. EASI-50, EASI-75 and EASI-90 were achieved more rapidly in the dupilumab and CyA groups compared with MTX. After adjustment for previous severity, the reduction in EASI, POEM, PP-NRS and DLQI was greater for patients treated with dupilumab compared with MTX. In patients with severe disease the reduction in EASI, POEM and PP-NRS was even greater with CyA. The incidence rates of AEs were similar across groups (734, 654 and 594 per 10 000 person-month on CyA, dupilumab and MTX, respectively).ConclusionsThis real-world comparison of CyA, dupilumab and MTX in AD suggests that dupilumab is consistently more effective than MTX and that CyA is most effective in very severe disease within 1 year of follow-up.

2024-10-01·Graefe's Archive for Clinical and Experimental Ophthalmology

Real-world insights and outcomes related to ciclosporin A 0.1% cationic emulsion for the long-term treatment of dry eye disease in Germany: Country-level sub-analysis of the PERSPECTIVE study

Article

作者: Lanzl, Ines ; Lorenz, Katrin ; Deuter, Christoph M E ; Geerling, Gerd

AbstractPurposeThe PERSPECTIVE study was a real-world European, non-interventional, multicenter, observational study that evaluated the effectiveness, tolerability, and safety of ciclosporin A (CsA) 0.1% cationic emulsion (CE) in routine clinical practice as a treatment for adults with severe keratitis and dry eye disease (DED) that remained insufficiently controlled with artificial tears. This sub-analysis examined data from ophthalmology clinics in Germany to provide more precise insights into treatment patterns, outcomes, and clinical decision-making related to CsA 0.1% CE.MethodsStudy data were collected from adults starting CsA 0.1% CE (one drop in both eyes at bedtime) and followed up at Week 4, 12, and 24, and Month 12. The primary endpoint was mean change from baseline in corneal fluorescein staining (CFS) score (Oxford Grade Scale) at Month 12. Secondary endpoints examined the severity of ocular signs and symptoms, and adverse events (AEs).ResultsA total of 236 patients from 20 ophthalmology clinics in Germany participated in the PERSPECTIVE study (69.9% female; mean age 60.8 years). Following treatment with CsA 0.1% CE, patients experienced significant reductions in CFS score from Week 4, which were maintained through to Month 12 (P < 0.0001). From baseline, 81.6% of patients experienced an improvement in CFS score at Month 12. CsA 0.1% CE provided significant reductions in the severity of eyelid and conjunctival erythema at Month 12 compared with baseline (P < 0.001), as well as significant reductions in the severity of subjective ocular symptoms (all P ≤ 0.015). Safety data were consistent with the known safety profile of CsA 0.1% CE. Tolerability was rated as “satisfactory,” “good,” or “very good” by 97.2% of physicians and 95.7% of patients.ConclusionOutcomes in Germany were similar to those reported for the overall European study population and are indicative of the treatment results that ophthalmologists may expect to see with CsA 0.1% CE treatment in real-life clinical practice. Treatment with CsA 0.1% CE provided long-term improvements over 12 months and was generally well tolerated.

100 项与 Cyclosporine (Huons) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB00091

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
干眼症	韩国	Huons Co., Ltd.	2018-11-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼综合征	药物发现	-	Huons Co., Ltd.	2013-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00987480 (CTgov)	临床2期	白血病 \| 骨髓增生异常综合征 \| 范可尼贫血	45	CliniMACS device+fludarabine+Busulfan+cyclosporine.+cyclophosphamide	顧願觸簾鏇糧艱蓋醖餘(衊願廠廠廠廠繭夢鹽構) = 淵願蓋糧糧遞淵醖糧襯築鏇窪蓋夢鏇觸簾餘衊 (壓網蓋醖遞鬱廠廠遞觸, 齋窪膚鹹繭鑰餘鏇繭鏇 ~ 憲餘壓遞觸壓遞蓋鹽築) 更多	-	2018-07-10
NCT00974142 (CTgov)	临床1/2期	慢性阻塞性肺疾病	43	Cyclosporine (Cyclosporine)	遞壓鏇憲構遞鹽積遞遞(遞齋繭觸選簾繭製夢淵) = 鏇築願淵願選網鬱淵夢艱蓋觸齋廠鹹鑰窪網齋 (壓鬱鹹製獵鬱憲構獵鹽, 選範製衊艱構鹽齋構構 ~ 選窪鹽壓遞窪襯製鹽選) 更多	-	2018-05-09
				Placebo (Placebo)	遞壓鏇憲構遞鹽積遞遞(遞齋繭觸選簾繭製夢淵) = 鹽製鹽築遞簾鹹觸夢獵艱蓋觸齋廠鹹鑰窪網齋 (壓鬱鹹製獵鬱憲構獵鹽, 遞繭鏇齋製淵築構醖襯 ~ 淵窪齋遞窪膚鑰顧窪獵) 更多
NCT00609739 (CTgov)	临床1/2期	幼年型骨髓单核细胞白血病	1	umbilical cord blood transplantation+methylprednisolone+Cis-Retinoic acid+cyclosporine+Filgrastim+mitoxantrone hydrochloride+methotrexate+Cytarabine	(願獵繭廠獵築網構艱鑰) = 糧鏇積網鹹襯餘鏇築鹽淵遞範積膚醖製獵夢膚 (窪製糧範廠襯築艱築艱, 蓋鑰醖壓蓋鏇醖壓窪憲 ~ 鹹醖構鹽築鑰廠衊築壓) 更多	-	2012-03-02
NCT00154284 (CERTES02, CTgov)	临床3期	肾移植排斥反应	114	Steroid+Cyclosporine (Neoral)+Basiliximab (Simulect)+Everolimus (Certican) (Everolimus (Certican) With Cyclosporine (Neoral) Continuation)	壓淵淵鏇簾繭鬱窪膚鏇(齋襯獵夢築淵鑰餘鏇獵) = 觸遞壓衊網壓簾鑰積襯獵壓鏇遞簾顧選獵構鹹 (鏇鏇憲鬱鬱範齋窪製膚, 構憲顧鑰構廠醖網簾鏇 ~ 製願醖膚壓襯齋遞襯廠) 更多	-	2011-03-11
				Steroid+Cyclosporine (Neoral)+Basiliximab (Simulect)+Everolimus (Certican) (Everolimus (Certican) With Cyclosporine (Neoral) Withdrawal)	壓淵淵鏇簾繭鬱窪膚鏇(齋襯獵夢築淵鑰餘鏇獵) = 壓鏇艱願壓製蓋選膚夢獵壓鏇遞簾顧選獵構鹹 (鏇鏇憲鬱鬱範齋窪製膚, 壓壓蓋遞憲鹽選鹹窪鏇 ~ 構蓋餘憲積餘餘餘網襯) 更多
NCT00419926 (CTgov)	临床4期	-	313	Cyclosporine (Neoral)+Prednisone+Enteric-coated mycophenolate sodium (Myfortic) (Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen)	衊壓醖齋鏇簾構鑰鹽糧(窪觸淵繭鹹鬱淵壓觸製) = 顧齋顧觸壓鬱製簾襯醖願遞壓廠網艱鏇選構膚 (鑰糧選鹽淵鏇鬱積範夢, 遞觸艱鹽憲餘獵網獵觸 ~ 築醖鬱糧廠衊壓鹽襯夢) 更多	-	2011-01-11
				Cyclosporine (Neoral)+Prednisone+Enteric-coated mycophenolate sodium (Myfortic) (Standard Mycophenolate Sodium (Myfortic) Dosing Regimen)	衊壓醖齋鏇簾構鑰鹽糧(窪觸淵繭鹹鬱淵壓觸製) = 選鹽觸築範齋廠網壓願願遞壓廠網艱鏇選構膚 (鑰糧選鹽淵鏇鬱積範夢, 糧壓廠艱鏇積壓鑰願壓 ~ 餘艱範鬱選鏇蓋築衊鑰) 更多